CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference

Rhea-AI Summary

CalciMedica (Nasdaq: CALC), a clinical-stage biopharmaceutical company specializing in CRAC channel inhibition therapies, announced its participation in the upcoming H.C. Wainwright 4th Annual Kidney Virtual Conference. CEO Rachel Leheny, Ph.D. will engage in a fireside chat on July 14, 2025, at 2:00 p.m. ET.

The presentation will be accessible through a live webcast in the "IR Events and Presentations" section of CalciMedica's investor relations website, with a replay available for 90 days following the event.

LA JOLLA, Calif., July 8, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference on Monday, July 14, 2025, at 2:00 p.m. ET.

A live webcast of the presentation can be accessed in the "IR Events and Presentations" section of CalciMedica's IR website. A replay of the webcast will be archived on the Company's website for 90 days.

About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials and been well-tolerated in over 350 critically ill patients dosed. CalciMedica has announced data for a Phase 2b trial (called CARPO – NCT04681066) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS) and for a Phase 2 trial (called CARDEA – NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE –NCT06374797) in patients with acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF). For more information, please visit www.calcimedica.com.

Contact Information
Argot Partners
calcimedica@argotpartners.com
(212) 600-1902

View original content to download multimedia:https://www.prnewswire.com/news-releases/calcimedica-to-participate-in-the-hc-wainwright-4th-annual-kidney-virtual-conference-302499225.html

SOURCE CalciMedica, Inc.

FAQ

When is CalciMedica (CALC) presenting at the H.C. Wainwright Kidney Conference 2025?

CalciMedica's CEO Rachel Leheny will present at a fireside chat on Monday, July 14, 2025, at 2:00 p.m. ET.

How can investors access CalciMedica's (CALC) presentation at the H.C. Wainwright conference?

Investors can access the presentation via live webcast in the 'IR Events and Presentations' section of CalciMedica's IR website. A replay will be available for 90 days afterward.

What type of therapies is CalciMedica (CALC) developing?

CalciMedica is developing calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses.

Who will represent CalciMedica (CALC) at the H.C. Wainwright Kidney Conference?

Rachel Leheny, Ph.D., CalciMedica's Chief Executive Officer, will represent the company in a fireside chat presentation.